

Traumatic Brain Injury Study Begins Recruiting Patients

Breakthrough multi-million dollar study funded by the U.S. Department of Defense

New York, NY, USA - November 14, 2011 – Remedy Pharmaceuticals, Inc. today announced that a Phase 2 clinical trial of its lead candidate RP-1127 for the treatment of moderate and severe acute Traumatic Brain Injury (TBI) has begun recruiting patients at the University of California at San Diego Trauma Center.

The randomized, double-blind, placebo-controlled clinical trial is being conducted by the INTRuST Consortium, a group of clinical study centers in the United States funded by a U.S. Department of Defense award to advance treatments and medical research in PTSD and traumatic brain injury.

This public-private collaboration is studying RP-1127 under Remedy's Investigational New Drug Application (IND) filed with the Food and Drug Administration (FDA). The trial is being performed in the United States and is designed to enroll approximately 100 moderate and severe TBI patients. It is anticipated that the information gained in the study will assist the Company in developing a larger Phase 3 study for this patient population.

The study's Principal Investigator is Howard Eisenberg, MD, R.K. Thompson Professor and Chairman, Department of Neurosurgery, University of Maryland School of Medicine. Dr. Eisenberg has been Principal Investigator on numerous high profile TBI studies.

The INTRuST trial leader is UCSD's Lawrence F. Marshall, MD, an internationally renowned research expert in traumatic head injury and creator of the Marshall CT classification, the *de facto* standard in traumatic brain injury for determining prognosis.

"There are currently no approved pharmaceutical therapies for TBI. This study is an important step in addressing this critical need," said Sven Jacobson, Chief Executive Officer of Remedy.

Detailed information for this study is available at:
<http://clinicaltrials.gov/ct2/show/NCT01454154>

About RP-1127

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca}-ATP channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com